BRAF and melanoma: As Table 2 indicates, we found BRAF activating mutations in 24 CUP cases, one of which was a melanoma without evidence for EGFR pathway alterations while more than half of the remaining twenty-three cases show potential EGFR pathway activation, suggesting they may not be ideal candidates for BRAF targeted mono-therapy.